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The use of human embryonic stem cells (hESCs) for regenerative medicine currently faces several hurdles,
including immune rejection of transplanted cells. Now inCell StemCell, Rong et al. (2014) describe a strategy
to protect hESCs from immune rejection while avoiding systemic immunosuppression, potentially facilitating
clinical implementation of hESC-based therapies.Human embryonic stem cells (hESCs) are
pluripotent cells that have the capacity to
differentiate into all cell types. This feature
makes them an attractive potential source
of material for use in cell-based therapies.
Transplantation of hESC-derived cells
holds great promise for regenerative
medicine (Chien, 2008; Cohen and
Melton, 2011) and could lead to novel
treatments for myocardial infarction,
stroke, diabetes, and other prominent hu-
man diseases. However, major hurdles
still need to be overcome to fully realize
this potential, including the prevention of
allogeneic rejection of transplanted hESC-
derived cells by the recipient’s immune
system (Boyd et al., 2012). One strategy
toprotecthESC-derivedcells fromimmune
rejection is the use of immunosuppressive
drugs. However, apart from their general
toxicity, these drugs also cause general
immunosuppression and can therefore in-
crease the risk of infection and cancer. In
this issue of Cell Stem Cell, Rong et al.
(2014) describe an approach to effectively
prevent allogeneic rejection of hESC-
derived cells without inducing systemic
immunosuppression.
This approach is based on the crea-
tion of a local immunosuppressive milieu
around the transplanted hESC-derived
cells by inhibiting the activation of T lym-
phocytes, the major immune cell type
responsible for rejection. To this end, the
authors engineered hESC lines to consti-
tutively express two molecules that target
costimulatory and coinhibitory pathways
in T lymphocytes (Bour-Jordan et al.,
2011). The modified hESCs secrete a
cytotoxic T lymphocyte antigen 4-immu-
noglobulin fusion protein (CTLA4-Ig)which blocks the interaction of costimula-
tory B7 molecules (expressed by antigen-
presenting cells) with the CD28 receptor
on the surface of T lymphocytes (Figure 1).
Engineered hESCs also express pro-
grammed death ligand-1 (PD-L1) on their
cell surface. PD-L1 engages the inhibitory
receptor PD-1 on T lymphocytes. Both
molecules were introduced into a single
BAC targeting vector and inserted into
the Hprt locus via homologous recombi-
nation. Importantly, the authors showed
that correctly targeted CTLA4-Ig/PD-L1
knockin hESCs retain their pluripotency
and can form teratomas in mice, similar
to unmodified hESCs.
To test if CTLA4-Ig/PD-L1-expressing
hESC-derived cells are protected from
allogeneic rejection, Rong et al. took
advantage of mice reconstituted with
a human immune system (humanized
mice) (Rongvaux et al., 2013; Shultz
et al., 2012). The use of humanized mice
allowed the authors to examine rejection
of hESC-derived cells by human immune
cells, which is a particularly important
consideration given the many species-
specific differences between the immune
systems of mice and humans (Mestas
and Hughes, 2004). To generate human-
ized mice, immunodeficient NOD-SCID
Il2rg/ (NSG) mice lacking mouse T, B,
and NK cells were transplanted with
human CD34+ fetal liver cells. The latter
contain hematopoietic stem and progeni-
tor cells that develop into human immune
cells in themouse host. Cotransplantation
of human fetal thymuswasalsoperformed
to support human T cell development.
Using this system, the authors demon-
strated robust rejection of teratomasCell Stem Celderived from control hESCs, as indicated
by necrosis of the teratomas and infil-
tration with human T cells. In contrast,
hESC-derived cells constitutively ex-
pressing CTLA4-Ig and PD-L1 were
protected from immune rejection and
displayed reduced infiltration by human
T cells. Importantly, this effect was not
limited to hESC-derived teratomas. Fibro-
blasts and cardiomyocytes differentiated
from CTLA4-Ig/PD-L1-expressing hESCs
were also protected from immune rejec-
tion. The authors confirmed these results
with two independent hESC lines and
additionally demonstrated that expres-
sion of both CTLA4-Ig and PD-L1
was required for efficient suppression
of the host immune response, as knockin
hESCs expressing either factor alone
were not protected from rejection. This
suggests a synergistic effect between
these factors, and constitutive expression
of CTLA4-Ig and PD-L1 conferred pro-
tection of grafted hESC-derived cells for
up to 3 months (the latest time point
analyzed). Next, Rong et al. addressed
whether the transplantation of CTLA4-Ig/
PD-L1 knockin hESCs caused systemic
immunosuppression. To evaluate this
possibility, unmodified and CTLA4-Ig/
PD-L1-expressing hESCs were simulta-
neously injected subcutaneously into
opposite flanks of the same animal. The
observation that unmodified hESCs were
rejected in these mice argues against
a general immunosuppressed state. In
further experiments, unmodified hESCs
were rejected in mice that had previously
been engrafted with CTLA4-Ig/PD-L1-
expressing hESCs, which were removed
before transplantation with the controll 14, January 2, 2014 ª2014 Elsevier Inc. 3
Figure 1. Protection of CTLA4-Ig/PD-L1 Knockin hESCs from Immune Rejection
Parental hECS are rejected by human T cells in mice with a reconstituted human immune system (top). In
contrast, hESC that constitutively express CTLA4-Ig and PD-L1, and differentiated cells derived from
these engineered hESCs, escape rejection by creating a local immunosuppressive environment (bottom).
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for lack of systemic immunosuppression.
Several open questions remain
regarding the immunoprotected state
of cells derived from CTLA4-Ig/PD-L1
knock-in hESCs. First, the mechanisms
underlying immune acceptance have not
been completely resolved. In addition to
reduced T cell infiltration, the authors
observed that the T cells that infiltrate
CTLA4-Ig/PD-L1 knock-in hESC-derived
teratomas express high levels of the
immunosuppressive cytokines TGFb
and IL-10, which could account for im-
munoprotection. However, frequencies
of regulatory T cells in teratomas from
control and CTLA-Ig/PD-L1-expressing
hESCs (as a percentage of total infiltrating
T cells) were similar despite increased
expression of IL-2, an important cytokine
that boosts regulatory T cell levels, in
the total T cell population purified from
CTLA-Ig/PD-L1 teratomas. Thus, addi-
tional detailed studies are required to
clarify the mechanisms underlying local
immune tolerance. Second, immune
responses to a more physiological (i.e.,4 Cell Stem Cell 14, January 2, 2014 ª2014 Enon-hESC) antigen challenge such as
immunization or infection should be
examined to provide additional experi-
mental support for the lack of systemic
immunosuppression after transplantation
with CTLA4-Ig/PD-L1-expressing cells.
Finally, immune tolerance might vary
between different sites/tissues where
CTLA4-Ig/PD-L1 knockin hESC-derived
cells are transplanted.
In conclusion, Rong et al. successfully
developed a novel approach to prevent
hESC rejection, which could facilitate the
application of hESC-based therapies to
treat human disease. Recent work has
focused on transplantation of syngenic
induced pluripotent stem cells (iPSCs)
(Araki et al., 2013; Guha et al., 2013),
and it will be interesting to compare the
immunogenicity of allogeneic engineered
hESCs with syngenic human iPSCs
in this humanized mouse model. The
approach described by Rong et al. could
provide a way forward for allogeneic
hESC-derived cell therapy as a safe alter-
native to syngenic iPSCs. For the clinical
application of this approach, potentiallsevier Inc.safety issues need to be kept in mind.
One is the random integration of exoge-
nous DNA into hESCs during the intro-
duction of the CTLA4-Ig-IRES-PD-L1
expression cassette in vitro. This risk
is minimized by the authors’ knockin
approach and can be excluded by
whole-genome sequencing of modified
hESC-derived cells before transplanta-
tion. Another concern is that grafted cells
derived from CTLA4-Ig/PD-L1 knockin
hESCs could undergo oncogenic trans-
formation or become a reservoir for
pathogenic viruses, particularly in the
setting of chronic engraftment of a pa-
tient. This would be particularly serious
since these cells are immune-privileged
and could therefore expand unchecked
in the human host. The study by Rong
et al. also demonstrates the usefulness
of humanized mouse models for preclini-
cal testing of therapeutic strategies that
are relevant in humans and provides
another potential path forward for human
embryonic stem cells in regenerative
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